Current Canadian drug legislation prohibits legal use of most psychedelic medicines (excluding ketamine). However, there are some ways to access legal psychedelic medicine currently, i.e., through Section 56 exemptions and the Special Access Program (SAP). Changes in Canadian psychedelic drug policy are emerging in Alberta and other provinces. These new policies and regulations have the potential to set a precedent for the rest of Canada. However, concerns have been noted with these proposed changes and their impact on access. Furthermore, Indigenous perspectives have often been left out of the landscape of drug policy and research. Join MAPS Canada as we provide exposition on the current regulatory landscape and bring together practitioners in the field of psychedelic therapy and science to discuss their experiences with access under the current regulatory framework, as well as their hopes for and concerns with future regulations pertaining to psychedelic medicines and treatments.
Description & Learning Objectives
FREE PREVIEWMeet Your Instructors
FREE PREVIEWEmerging Regulatory Frameworks for Psychedelics in Canada: Impact on Access
Examine and explain the current Canadian regulatory landscape as it pertains to psychedelics.
Provide insights on Indigenous sovereignty and relations between First Nations and the Nation of Canada in relation to healing practices.
Discuss the emerging changes in the regulatory landscape for psychedelic therapy in Canada.
Discuss practitioner’s perspective of the changing regulatory landscape and its impact on ensuring safe and effective access to psychedelic medicines and treatments.
